A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD) -

OVARTIS PHARMA AG0 sites1,144 target enrollmentMay 25, 2021

ConditionsAlzheimer's disease MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852 Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Alzheimer's disease
Sponsor: OVARTIS PHARMA AG
Enrollment: 1144
Status: Active, not recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

May 25, 2021

End Date

March 26, 2020

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

OVARTIS PHARMA AG

Eligibility Criteria

Inclusion Criteria

•Screening part I: Participants eligible for inclusion must fulfill all of the following criteria prior to scheduling the genetic disclosure.
•1\. Written informed consent must be obtained before any assessment is performed as part of the study, including consent to receive disclosure of their risk estimates to develop clinical symptoms of AD based on their APOE genotype and, if HTs, with evidence of elevated brain amyloid.
•2\. Male or female, age 60\-75 years inclusive, at the time of signing the informed consent. To ensure that no more than 20% of participants in the age group 60\-64 years are randomized across the whole recruitment period, a site level process will be implemented.
•3\. Females must be considered post\-menopausal and not of child bearing potential i.e. they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. history of vasomotor symptoms), or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation.
•4\. Intellectually, visually and auditorily capable, fluent in, and able to read, the language in which study assessments are administered (e.g. completion of at least 6 years of regular schooling or sustained employment or equivalent local level of knowledge).
•5\. Mini\-Mental State Examination total score \=24\.
•6\. Willing to have a study partner throughout the study. Screening part II: Participants eligible for inclusion must fulfill all of the following criteria prior to randomization based on the results from the screening test procedures.
•7\. Carrier of at least one e4 allele of the APOE gene: HMs with elevated or not elevated brain amyloid OR HTs with elevated brain amyloid (as measured in CSF collected via lumbar puncture or by amyloid PET imaging).
•Note: In cases where both lumbar puncture (CSF) amyloid and amyloid PET imaging tests are performed, at least one should be indicative of elevated brain amyloid.
•8\. Cognitively unimpaired at screening visit as defined by: Score of 85 or greater on the RBANS delayed memory index score AND CDR global score of 0 with two special exceptions: a) If the RBANS delayed memory index score is between 70 and 84 (inclusive) AND the global CDR \= 0, the participant may be allowed to continue ONLY if the investigator judges that cognition is unimpaired following review of the MCI/dementia criteria; b) If the global CDR score \= 0\.5 AND the RBANS delayed memory index score is 85 or greater, the participant may be allowed to continue ONLY if the investigator judges that cognition is unimpaired following review of the MCI/dementia criteria.

Exclusion Criteria

•Screening part I: Participants will be excluded if they fulfill any of the following criteria prior to scheduling the genetic disclosure.
•1\. Current medical or neurological condition that might impact cognition or performance on cognitive assessments e.g. MCI, dementia, Huntington's or Parkinson's disease etc.
•2\. Advanced, severe progressive or unstable disease that may interfere with the safety, tolerability and study assessments, or put the participant at special risk e.g. active hepatitis, HIV infection, severe renal impairment, severe hepatic impairment etc.
•3\. History of malignancy of any organ system, treated or untreated, within the past 60 months, regardless of whether there is evidence of local recurrence or metastases. However, localized nonmalignant tumors not requiring systemic chemo\- or radio\-therapy, localized basal or squamous cell carcinoma of the skin, in\-situ cervical cancer are
•permitted. 4\. Current treatment with Cholinesterase Inhibitors and/or another AD treatment.
•5\. Clinically relevant depigmenting or hypopigmenting conditions or active/history of chronic urticaria in the past year.
•6\. Score yes on item 4 or 5 of the Suicidal Ideation section of the eCSSRS patient\-reported outcome, if this ideation occurred in the past 6 months, or yes on any item of the Suicidal Behavior section, except for the Non\-Suicidal Self\- Injurious Behavior, if this behavior occurred in the past 2 years prior to screening.
•7\. Lacking psychological readiness to receive APOE genotype/amyloid status results, as assessed based on investigator's judgement supported by the pre\-disclosure rating scales: Geriatric Depression Scale total score \>6; Six Item Subset Inventory of the modified State Trait Anxiety Inventory total score \>17\.
•8\. Use of other investigational drugs prior to screening until: Small molecules: after 5 half\-lives, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; Biologicals: blood concentration has returned to baseline (or below serological responder threshold) for antibodies induced by active immunotherapy; or 5 half\-lives for monoclonal antibodies or other biologicals.
•9\. Treatment a) in the 4 weeks prior to randomization with any drug or treatment known for the potential to cause major organ system toxicity i.e. drugs that may require periodic safety monitoring of a specific organ or body fluid.